Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression
Many patients fail to achieve an adequate response to antidepressant medication. Growing evidence suggests that atypical antipsychotics may augment antidepressant effects, resulting in a greater potential for response. Atypical antipsychotics possess pharmacological actions that are associated with antidepressant properties, including serotonin 5-HT2 receptor antagonist and 5-HT1A and dopamine receptor partial agonist activity. In fact, the term ‘atypical antipsychotic’ is an unfortunate remnant of the early indication of these drugs in the treatment of schizophrenia. Soon after their introduction, the usefulness of atypical antipsychotics in bipolar disorder was firmly established and their use in the treatment of mood disorders has far outpaced their use in schizophrenia and other psychotic disorders. Aripiprazole has become the first agent to receive US FDA approval for the adjunctive treatment of unipolar depression. Most recently, Symbyax, a fluoxetine/olanzapine combination, received FDA approval for the acute treatment of treatment-resistant depression. This is the first medication to be FDA approved for this indication. In the present article, the usefulness of antipsychotics in the treatment of resistant unipolar depression is reviewed.
No sources of funding were used to assist in the preparation of this review. Dr DeBattista receives grant support from AstraZeneca, Lilly, Wyeth, GlaxoSmithKline, Pfizer, Cephalon, Novartis, Neuronetics, Cyberonics, Medtronics and CNS Response, and is on the speaker’s bureau for Lilly, Wyeth, Cephalon, GlaxoSmithKline, Pfizer, Cyberonics and Bristol Myers Squibb. In addition, Dr DeBattista is a stock holder of Corcept Therapeutics. Jessica Hawkins has no conflicts of interest to declare that are directly relevant to the content of this review.
- 8.Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005; 66 Suppl. 8: 30–40Google Scholar
- 10.Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008 Apr 16; (2): CD006722Google Scholar
- 23.Mattingly GLH, Canale J, Anderson R. Quetiapine combination for treatment resistant depression. 159th Meeting of the American Psychiatric Association; 2006 May 20—25; Toronto (ON)Google Scholar